The specter of generic challenges has consistently loomed around copyright’s iconic drug, Sildenafil, sparking questions about the prospects of similar medicinal portfolios. While early times saw impressive gains, the intellectual property end has allowed the door for discounted substitutes, possibly diminishing profitability and creating a genui